Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy

Human Pathology

Volumn 44, Issue 3, 2013, Pages 310-319

  Mirtti, Tuomas ^a,b,c   Leiby, Benjamin E ^c   Abdulghani, Junaid ^c   Aaltonen, Elina ^d   Pavela, Miia ^d   Mamtani, Anita ^c   Alanen, Kalle ^d   Egevad, Lars ^e   Granfors, Torvald ^f   Josefsson, Andreas ^g   Stattin, Par ^g   Bergh, Anders ^g   Nevalainen, Marja T ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF TURKU   (Finland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f CENTRAL HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY   (Sweden)

Author keywords

Prostate cancer; Prostate cancer specific death; Recurrence; Stat5a b; Therapy failure

Indexed keywords

STAT5A PROTEIN; STAT5B PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84873726593     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.06.001     Document Type: Article

References (34)

1. K.A. Roehl, M. Han, C.G. Ramos, J.A. Antenor, and W.J. Catalona Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910 914
2. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
3. J.I. Epstein An update of the Gleason grading system J Urol 183 2010 433 440
4. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
5. S.E. Eggener, P.T. Scardino, and P.C. Walsh Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
6. J.E. McNeal, and D.F. Gleason Gleason's classification of prostatic adenocarcinomas Ann Pathol 11 1991 163 168
7. T.J. Ahonen, P.L. Harkonen, J. Laine, H. Rui, P.M. Martikainen, and M.T. Nevalainen Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture Endocrinology 140 1999 5412 5421
8. T.J. Ahonen, P.L. Harkonen, H. Rui, and M.T. Nevalainen PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro Endocrinology 143 2002 228 238
9. H. Li, T.J. Ahonen, and K. Alanen Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade Cancer Res 64 2004 4774 4782
10. M.T. Nevalainen, E.M. Valve, T. Ahonen, A. Yagi, J. Paranko, and P.L. Harkonen Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture FASEB J 11 1997 1297 1307
11. M.T. Nevalainen, E.M. Valve, P.M. Ingleton, and P.L. Harkonen Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate Endocrinology 137 1996 3078 3088
12. M.T. Nevalainen, E.M. Valve, P.M. Ingleton, M. Nurmi, P.M. Martikainen, and P.L. Harkonen Prolactin and prolactin receptors are expressed and functioning in human prostate J Clin Invest 99 1997 618 627
13. M.T. Nevalainen, E.M. Valve, S.I. Makela, M. Blauer, P.J. Tuohimaa, and P.L. Harkonen Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture Endocrinology 129 1991 612 622
14. J.E. Darnell Jr. STATs and gene regulation Science 277 1997 1630 1635
15. J.N. Ihle, T. Nosaka, W. Thierfelder, F.W. Quelle, and Shimoda K. Jaks Stats in cytokine signaling Stem Cells 15 Suppl. 1 1997 105 111 [discussion 112]
16. T.J. Ahonen, J. Xie, and M.J. LeBaron Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells J Biol Chem 278 2003 27287 27292
17. A. Dagvadorj, S. Collins, and J.B. Jomain Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway Endocrinology 148 2007 3089 3101
18. A. Dagvadorj, R.A. Kirken, B. Leiby, J. Karras, and M.T. Nevalainen Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo Clin Cancer Res 14 2008 1317 1324
19. L. Gu, P. Vogiatzi, and M. Puhr Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo Endocr Relat Cancer 17 2010 481 493
20. A.V. Kazansky, D.M. Spencer, and N.M. Greenberg Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system Cancer Res 63 2003 8757 8762
21. C. Thomas, A. Zoubeidi, and H. Kuruma Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo Mol Cancer Ther 10 2011 347 359
22. S.H. Tan, A. Dagvadorj, and F. Shen Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells Cancer Res 68 2008 236 248
23. L. Gu, A. Dagvadorj, and J. Lutz Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth Am J Pathol 176 2010 1959 1972
24. H. Li, Y. Zhang, and A. Glass Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence Clin Cancer Res 11 2005 5863 5868
25. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of Malignant Tumours 2009 Wiley-Blackwell Hoboken, NJ
26. P. Hammarsten, A. Karalija, and A. Josefsson Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients Clin Cancer Res 16 2010 1245 1255
27. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
28. D.F. Gleason Classification of prostatic carcinomas Cancer Chemother Rep 50 1966 125 128
29. D.F. Gleason Histologic grading of prostate cancer: a perspective Hum Pathol 23 1992 273 279
30. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
31. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459 3464
32. G.J. Netto, M. Eisenberger, and J.I. Epstein Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 Multinational Clinical Trial Urology 77 2011 1155 1160
33. T. Oyama, W.C. Allsbrook Jr., and K. Kurokawa A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States Arch Pathol Lab Med 129 2005 1004 1010
34. C.P. Evans Identification of molecular targets in urologic oncology World J Urol 27 2009 3 8